MDT · News · 20261105N

Evolut TAVR Clinical Positioning

Medtronic plc · 2026-11-05 · Importance 33 · Surprise 24

At the TCT annual conference, Medtronic presented the design and baseline characteristics of the Evolut EXPAND TAVR II trial. The global randomized study is evaluating the Evolut TAVR platform in patients aged 65 or older with moderate aortic stenosis and additional risk factors. It compares TAVR plus guideline-directed medical therapy with medical therapy alone to assess clinical outcomes. The trial enrolled 692 patients across 96 sites in 16 countries.

Key facts

• The global randomized Evolut EXPAND TAVR II Trial is investigating whether TAVR intervention with guideline-directed medical therapy improves clinical outcomes compared with medical therapy alone in patients with moderate aortic stenosis. source
• The Evolut EXPAND TAVR II Trial includes 692 patients from 96 sites in 16 countries, aged 65 or older, with moderate aortic stenosis and additional risk factors. source
• Medtronic presented the study design and baseline characteristics of patients enrolled in the Evolut EXPAND TAVR II Trial at the TCT annual conference. source